Nuvessa is a prescription metronidazole 1.3% vaginal gel supplied as a single-dose prefilled applicator for an FDA-labeled bacterial vaginosis indication. Its payment and insurance questions differ from those for traditional 0.75% vaginal gel products. When asking a pharmacy for a quote, identify the 1.3% concentration and complete single-dose package rather than searching for metronidazole gel without a route or strength. Start with the Nuvessa brand guide for product identity.
An important regulatory update changes how 'brand only' claims should be interpreted. FDA approved Encube Ethicals' metronidazole vaginal gel 1.3% under ANDA 216795 in March 2024, and DailyMed carries a generic 1.3% label. An FDA-approved generic therefore exists. That fact does not establish the product's present availability at a particular pharmacy, an insurance plan's preferred status or a guaranteed price advantage. Both a branded and a generic quote require verification.
This page focuses on Nuvessa-specific cost and coverage choices: whether the plan recognizes the prescribed product, possible brand-versus-generic handling, the single applicator package and what to ask after an insurance rejection. It contains no live prices or discount guarantees. Conventional 0.75% gel pricing is kept on the separate vaginal gel cost page so the different products are not conflated.
Nuvessa 1.3% is a vaginal metronidazole gel, not a rosacea skin product. Its labeling describes a specific single-dose prefilled applicator. A 'metronidazole vaginal gel' search may instead return 0.75% multidose formulations, different carton formats or archived brand listings. Before seeking a quote, compare the actual order with the labeled product name, concentration, vaginal route and package quantity.
A unit price per gram is a poor comparison when products involve different strengths and labeled regimens. Do not interpret the single-dose presentation as permission to replace the prescribed product with a tube of another concentration. The prescriber selects treatment; the pharmacist checks whether a specific branded or approved generic item can be legally dispensed.
| Pharmacy listing | Cost question | Important distinction |
|---|---|---|
| Nuvessa 1.3% brand | Brand-specific benefit and single-dose package quote | Not a 0.75% vaginal gel carton |
| Approved generic metronidazole vaginal gel 1.3% | Exact ANDA product, coverage and availability | FDA approval does not guarantee retail stock |
| Generic vaginal gel 0.75% | Separate prescription and cost evaluation | Different concentration and labeled presentation |
| Topical metronidazole gel | Not part of Nuvessa cost comparison | Dermal product is not for vaginal use |
The FDA approval letter for ANDA 216795 names Encube's metronidazole vaginal gel 1.3% and establishes that an approved generic regulatory pathway exists. DailyMed separately identifies a prescription 1.3% vaginal gel under that ANDA. Consequently, a blanket statement that no FDA-approved Nuvessa generic exists is outdated. This is a product-status clarification, not a marketing claim or statement of a national price.
Patients still need a pharmacy to confirm whether the exact approved product can be ordered or dispensed. Plan formularies may list a brand and generic separately, and a pharmacy may need to check state substitution requirements or the prescriber's instructions. Regulatory approval must be kept separate from wholesaler distribution, local inventory and the amount actually charged.
Ask the insurer whether it covers Nuvessa by brand name and whether the approved 1.3% generic has a different listing, tier or restriction. A formulary search for 'metronidazole gel' may group vaginal 0.75%, vaginal 1.3% and dermatologic products in ways that are unhelpful without route filters. Request patient-specific benefit details for the exact NDC or approved product the pharmacy intends to dispense.
If the plan requires prior authorization or prefers another medicine, ask for the written rule and the prescriber's participation in any exception request. Coverage differences are not a reason for a patient to redesign a BV regimen independently. The vaginal prescription guide addresses why diagnosis and product choice precede benefit questions.
Generic competition can affect purchasing options, but the final patient amount still depends on pharmacy acquisition, plan contract, tier, deductible and dispensing circumstances. A branded product could cost differently under a particular plan than under cash payment, while a generic might be listed but not stocked locally. Comparing anonymous coupon results is especially unreliable when the listing omits the 1.3% concentration.
Request two quotes only if the pharmacy can identify an approved, appropriate item in each category and determine how the actual prescription can be filled. Record the complete single-dose package, payment path and any fees. Do not claim that an approved generic necessarily produces a lower charge in every transaction or that the generic is interchangeable with 0.75% vaginal gel.
A pharmacy can explain whether it is billing Nuvessa through insurance, quoting an ordinary cash amount or applying a valid discount arrangement. These transactions have different rules, and a third-party program may not be accepted for the product. Manufacturer programs, when they exist, may have separate eligibility conditions, particularly for government-funded plans. Do not presume a particular coupon is available or active.
Ask whether the quoted total covers the complete prefilled applicator carton, any required pharmacy service and delivery charges if relevant. A vague 'per tube' price is a warning sign when the product being discussed is a single-dose applicator. The oral discount guide discusses general payment distinctions; Nuvessa eligibility must be checked for the actual vaginal brand or generic.
Vandazole is a 0.75% vaginal metronidazole gel brand, while Nuvessa is a distinct 1.3% single-dose product. Both belong to the metronidazole vaginal family but are not interchangeable based on an attractive quote. Separate concentration, packaging and regimen labels require separate verification. The brand-specific Vandazole cost comparison is therefore not a competing Nuvessa pricing page.
A clinician may consider multiple BV treatment options, but the pharmacy transaction must follow the prescription actually issued. A lower cost for a different formulation is useful information to bring to a prescriber, not permission to change therapy. Keep the benefit inquiry aligned with the formulation and instructions.
A plan listing or DailyMed label does not tell you whether a pharmacy can fill the prescription now. Ask the pharmacy to check the prescribed branded item and, if the order permits, the exact approved generic. Clarify whether a product is out of stock, not carried or unavailable from its supplier; each has a different operational meaning.
If sourcing might delay appropriate care, contact the prescriber promptly. Only a professional can decide whether another formulation or treatment is suitable. The vaginal gel availability guide covers the distinction between approved products and real inventory, but does not offer a real-time stock feed.
Ask whether the item is Nuvessa 1.3% or an approved 1.3% generic, whether it is a single prefilled applicator, whether the pharmacy can obtain that specific product, how insurance treats it, whether authorization is necessary, what the all-in cash alternative would be, and which fees or program restrictions apply. Confirm all answers against the prescription before approving dispensing.
At pickup, read the vaginal-route label and verify the concentration and package with the pharmacist. Do not accept a dermatologic gel or a different concentration merely because the label contains the word metronidazole. An evergreen resource can explain these checks; it cannot establish a particular patient's coverage or current price.
Yes. FDA approved Encube Ethicals metronidazole vaginal gel 1.3% under ANDA 216795 in March 2024. That does not prove a particular pharmacy currently stocks it.
The U.S. label describes a single-dose prefilled vaginal applicator. The clinician and label determine appropriate use.
No such interchangeability can be presumed. The concentration and product presentation differ, and substitution requires professional review.
No. Coverage, restrictions and cost sharing depend on the individual plan and product it processes.
No. A lower price or pharmacy availability cannot be inferred from FDA approval alone.
The pharmacist must verify the exact approved product, the written prescription and applicable substitution law.
Do not assume so. Any discount must match the vaginal 1.3% product and participating pharmacy.
Nuvessa 1.3% and Vandazole 0.75% are different vaginal gel products with different labeled presentations.
Ask the pharmacy to clarify the supply issue and contact the prescriber about appropriate next steps. Do not choose another concentration yourself.
Not without current, product-specific transaction evidence. Confirm the complete quoted amount directly with a licensed dispensing pharmacy.